Multi-Arm, Nonrandomized, Open-Label Phase Ib Study to Evaluate Fp1039/Gsk3052230 with Chemotherapy in Nsclc and Mpm with Deregulated Fgf Pathway Signaling
Pilar Garrido(Hospital Universitario Ramón y Cajal), Ulrik Lassen(Rigshospitalet), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Shirish M. Gadgeel(Chinese University of Hong Kong), Jean‐Pierre Delord, Ignacio Delgado(Universitat Autònoma de Barcelona), Daniel Morgensztern(Barnes-Jewish Hospital), E. Levchenko(Research Medical Center), Santiago Viteri(Instituto Oncológico Dr. Rosell), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), José Trigo(Heidelberg University), Primo N. Lara(UC Davis Comprehensive Cancer Center), Fabrice Barlési(Hôpital Nord), Hedy L. Kindler(University of Chicago), Erin M. Bertino(The Ohio State University), Enriqueta Felip(Institut Català d'Ornitologia), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Johan Vansteenkiste, Sergey Orlov(St Petersburg University)
Cited by 3
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k